跳到正文
原文
Nature 健康护理主题·· 18 天前精选AI 评分80

德国冠心病患者接受结构化初级护理的长期益处:一项12年队列研究

Sustained long-term benefits of structured primary care for patients with coronary artery disease: a 12-year cohort study in Germany (2011–2022)

AI 导读

一项基于德国理赔数据的12年队列研究显示,接受GP中心化护理的冠心病患者住院率和全因死亡率显著降低,支持该模式在德国的进一步推广。

推荐理由

该研究展示了GP中心化护理模式对冠心病患者长期疗效的积极影响,支持其在德国的进一步推广。

正文

Abstract

In 2022, cardiovascular diseases accounted for 32.7% of all deaths in the EU, with associated costs of €282 billion annually. In Germany, coronary artery disease (CAD) remains the leading cause of mortality and recent reductions in life expectancy gains have been attributed to excess CVD mortality. High rates of avoidable hospital admissions suggest shortcomings in ambulatory care. In 2004, Germany introduced the general practitioner-centred care (‘Hausarztzentrierte Versorgung” (HZV)) programme with the aim of strengthening primary care. This longitudinal observational cohort (N = 125,758 in 2011, N = 169,101 in 2022) study based on German claims data describes the long-term effects of HZV on healthcare utilization and all-cause mortality for patients with CAD in observation period 2011–22. HZV participants had consistently lower odds of all-cause hospitalisation (OR 0.988, 95%CI, p < 0.001), CVD hospitalisation (OR 0.989, 95% CI, p < 0,001) and ambulatory care sensitive condition hospitalisation (OR 0.989, 95% CI, p < 0,001) in comparison to usual care. All-cause mortality reduced over the observation period and odds were significantly lower in the HZV group at the end of 2022 (OR 0.987, 95% CI, p < 0.001). These findings emphasise the role of structured, coordinated primary care in strengthening care for patients with CAD and support the broader implementation of GP-centred care models.

Introduction

In 2022, cardiovascular diseases (CVD) were leading cause of death in Europe, accounting for 32.7% of all deaths in the EU1, with associated costs of €282 billion annually2. Cardiovascular diseases (CVD), in particular myocardial infarction and stroke, are the main causes of morbidity and mortality in Germany, associated with correspondingly high medical costs3. 7.99% of the population in Germany is affected by coronary heart disease4, resulting annually in 574 hospital admissions per 100,000 inhabitants in 20235. Diseases of the circulatory system entailed costs of 56.7 billion euros in Germany in 20226.

Despite declines in mortality due to cardiovascular diseases in recent decades, a flattening of this trend has been observed in the past ten years7. Reported reductions in life expectancy gains have been attributed to excess CVD mortality, in particular amongst 50–64 years olds7. CVD mortality in Germany is predicted increase due to population ageing if the reduction in mortality rates continue to slow further8. Insufficient preventive care policies and low rates of early detection of CVD have been cited as causes for higher hospitalization and mortality rates in Germany compared to other high-income countries9. Monitoring and management of underlying risk factors has been identified as a public health priority8.

The number of avoidable hospital admissions can indicate the quality of ambulatory medical care10, as these patients can be treated effectively in an outpatient setting. Germany has one of the highest total number of avoidable hospital admissions in the EU, at 728 per 100 000 population in 2021, of which the largest proportion was related to heart failure. These comparatively higher rates may point to deficiencies within the primary care sector and coordination of care. Historically the clear delineation of ambulatory and hospital care within Germany has been a barrier for effective integration of care11.

Primary care plays a significant role in the prevention, identification of and treatment of cardiovascular diseases12. GPs are often the first contact for patients and in recent years there has been increased emphasis on the expanding role of primary care in prevention of CVD. Ensuring that patients with risk factors such as high blood pressure or elevated cholesterol are managed optimally in primary care can reduce the likelihood of experiencing a cardiovascular event such as myocardial infarction or stroke. GPs provide evidence-based lifestyle counselling to encourage healthy diet and recommended physical activity levels, regular monitoring and appropriate medication, as well as coordinating care for patients with established CVD, including referral to specialists. Preventing CVD can also help to prevent other conditions such as cancer, diabetes and dementia, due to common risks factors, such as smoking and obesity, amongst these diseases.

In 2004, Germany introduced the general practitioner-centred care (‘Hausarztzentrierte Versorgung” (HZV)) programme with the aim of delivering structured, coordinated and strengthened primary care. Closer collaboration with ambulatory specialists, including cardiologists, is an important component of HZV, as is multidisciplinary chronic disease management. Previous studies have shown improved clinical outcomes for patients with cardiovascular diseases13,14,15,16 within such care programmes. This study addresses specifically the long-term benefits in terms of healthcare utilisation and mortality within the GP-centred care programme in the federal state of Baden Württemberg in Germany. The HZV in Baden-Württemberg is a comprehensive, statewide, and scientifically evaluated care model with mandatory quality requirements, including regular participation in quality circles, mudlidisciplinary care involving primary care practice assistants (VERAH), interprofessional care coordoination, and structured collaboration with specialists. In contrast, other HZV models in Germany often focus primarily on mandatory general practitioner registration, without comparable requirements for care quality and coordination. Thus, the HZV in Baden-Württemberg represents a uniquely systematic and scientifically evaluated primary care programme, whereas other HZV models are often less comprehensively structured, implemented, or evaluated.

Methods

This retrospective cohort study constitutes a longitudinal examination of selected indicators over a multi-year period (2011–2022), among patients with coronary artery disease (CAD). Patients enrolled in HZV were compared with patients receiving standard care from general practitioners not participating in the programme. Both groups were drawn from the federal state of Baden-Wuerttemberg in southwest Germany, which has approximately 11 million inhabitants and a high participation rate in the primary care programme. Analyses were based on routinely collected healthcare data obtained from the administrative databases of the statutory health insurance fund Allgemeine Ortskrankenkasse (AOK) Baden-Wuerttemberg. This analysis was conducted as part of a wider evaluation of the HZV programme17.

Data basis

All AOK-insured individuals with an “epidemiologically confirmed” diagnosis of CAD between 2011 and 2022 were included, defined as an ICD-10 diagnosis coded as confirmed and recorded at least once in an inpatient setting or in at least two of three quarters in an outpatient setting within a one-year period. To enable an accurate comparison between the healthcare programmes (HZV and SC), a set of exclusion criteria was applied annually. Consequently, the populations analysed vary from year to year. Only patients who had visited a general practitioner at least once per year, were adults, maintained continuous health insurance coverage, resided in Baden-Württemberg and had the same general practitioner throughout the given year were considered. To ensure comparability of care, patients who generally seek direct specialist care (“high utilizers”) were excluded. Likewise, insured individuals treated in an HZV enrolled practice without participating in the HZV program themselves were excluded. Enrolled patients per year are described in Tables 1 and 2. There are no missing data in the German claims data used for this analysis, as only eligible insured individuals/patients with complete information were included in the study population. A patient flow diagram detailing inclusion/exclusion criteria is included in Appendix 3.

Table 1 Number and percentage of patients with CAD included annually.

Full size table

Indicators / outcome measures

The present analysis examines the development of quality of care within the HZV group and compares individuals enrolled in the HZV with non-enrolled insured individuals over multiple years. The list of covariates used for model adjustment is displayed in Appendix 1. The patient characteristics also reflect the variables of the multivariate analysis.

Table 2 Primary outcome indicators– recorded annually.

Full size table

Intervention

GP-centred care (HZV) is a complex intervention with multiple facets, as outlined in Table 3:

Table 3 Comparison of standard care versus GP-centred care in Germany19.

Full size table

Data processing

The raw data were transmitted from the AOK Baden-Württemberg to the aQua Institute, which performed an initial data quality check and verified data consistency, particularly across raw data tables. Based on a list of indicators, base datasets including target variables were generated, which were then provided to the research team. The data were pseudonymised before being transferred to the research team, which had no direct access to patient identifying information or the pseudonymisation key. Data processing and use were governed by a data protection agreement in accordance with General Data Protection Regulation (GDPR).

Statistical analysis

Descriptive statistics

A descriptive analysis of all target and explanatory variables was conducted. For continuous variables, mean and standard deviation were calculated; for categorical variables, absolute and relative frequencies were determined. These analyses were performed for the total CAD population and separately for the HZV and SC groups (Appendix 1).

Regression analysis of outcome variables

Group differences (HZV vs. SC) were analysed using a logistic generalized linear model fitted with Generalized Estimating Equations (GEE). An autoregressive covariance structure was assumed to account for the correlation of repeated observations for each patient. The patient (identified by versid) was the repeated subject in the GEE model. Because the study was conducted in an open cohort, patients were not required to contribute observations in every study year. We included each patient’s available patient-year records; patients contributed observations only in years in which they were observed, and no observations were imputed for years without a record.

To assess quality differences between the groups, the following components were included in the model:

  • Baseline group difference between HZV and SC (β1).

  • Annual trend in the SC group (β₂).

  • Difference in yearly change between HZV and SC.

The resulting estimators are to be interpreted as follows:

  • exp(β₁): Odds ratio (OR) for the groups, indicating the probability of experiencing a given event at the beginning of the observation period.

  • exp(β₂): Annual OR for the event in the SC group.

  • exp(β₃): Annual OR describing how the yearly trend in HZV differs from SC.

The figures visualize the model results by plotting the model-predicted values over time. The difference between the groups is reflected in the separation of the lines at the start of the period (2011); changes in this separation over time may indicate an interaction between time and group and the direction of such an interaction. Representative diagrams were created for the most important analyses.

The linear representation of trends reflects the model assumptions. To assess whether the assumption of linearity was justified, a sensitivity analysis was conducted using an alternative model in which the year was treated as a categorical variable. This model does not assume a linear trend. The corresponding estimates were also included in the figures to identify any substantial deviations from linearity.

A Bonferroni correction was applied by dividing the overall significance level (α = 0.05) by the number of tests (32), resulting in an adjusted threshold of α = 0.00156.

Results

Descriptive

In 2011, 125,758 patients with CAD were included in the study increasing to in 169,101 patients in 2022 (Table​ 1). Of the patients enrolled at the start of the study in 2011, 45.9% received standard care and 54.1% were enrolled in the GP-centred care programme. At the end of this study in 2022, 28.2% received standard care and 71.8% were enrolled in GP-centred care.

Appendix 2 shows the number and percentage of patients who in addition to HZV were also enrolled in the on-top collaborative ambulatory specialist care programme. Participants increased from 60,414 in 2011 to 78, 245 in 2022. At the end of the observation period 64% of HZV enrolled individuals were also enrolled in the on-top collaborative ambulatory specialist care programme.

Table 4 displays the sociodemographic data and clinical characteristics of the patients included at baseline in 2011 (unadjusted). Comorbidity prevalences demonstrated small differences between the HZV and standard care groups. The mean Charlson comorbidity index (CCI) was also similar (3.0 vs. 3.1). Enrolment rates for disease management programmes (DMP) were higher in GP-centred healthcare, which reflects incentivisation in GP-centred healthcare compared to usual care. The mean age in was similar in both groups (73.7 in GP-centred care vs. 74.3 in usual care). Regarding practice characteristics, HZV participants were more often enrolled at a group practice or urban practice. Covariate adjustment was performed in the further analyses to account for pre‑existing differences between the group.

Table 4 Patient characteristics of CAD cohort at baseline (2011).

Full size table

Multivariate analysis & longitudinal trends

Table 5 shows the statistical odds ratio of all observed outcomes at the start of the study and annual trend in SC and additional in HZV. Over the 12-year observation period, HZV participants had consistently lower odds of all-cause hospitalisation (OR 0.988, 95% CI: 0.985–0.990, p < 0.001), hospitalisation due to CVD (OR 0.989, 95% CI, p < 0.001) and ambulatory care sensitive condition hospitalisation (OR 0.989, 95% CI, p < 0.001) in comparison to usual care. Figures 1A-C show the longitudinal trends for the observed hospitalisation outcomes and demonstrate significantly lower and declining rates of all cause hospitalisation, CVD hospitalisation and ACSC hospitalisation in the HZV group over the observation period.

The odds of receiving statin therapy were lower in the HZV group at the start of the study but increased over the 12-year period, however odds were not significant (OR 1.003, 95%CI, p < 0.0046) at the end of the study. Figure 1D show the longitudinal trend and demonstrates consistently rising prescription rates in both HZV and usual care over the study period.

All-cause mortality risk reduced over the 12-year period and was significantly lower in the HZV group at the end of the study period (OR 0.987, 95% CI, p < 0.001). Figure 1E shows the longitudinal trend and demonstrates declining all-cause mortality rates in HZV over 12 years. The transitory increase in mortality rates in 2020-21 may reflect the impacts of the COVID-19 pandemic during these years20.

Table 5 Summary of odds ratios for chosen outcomes change per 1‑year increase in CAD patients from SC and HZV.

Full size table

Fig. 1

Longitudinal trend observations (marginal predicted percentage) for A) All-cause hospital admissions B) Hospital admission due to cardiovascular illness C) ACSC Hospital admission D) Statin Prescription E) All-cause Mortality. All outcomes are adjusted for the covariates listed in Appendix 1.

Discussion

GP-centred care (HZV) was consistently associated with lower health care utilisation (lower all-cause, CAD and ACSC admission rates) for patients with CAD, with sustainable and increasing advantages shown over the 12-year study period. The rate of hospital admissions in particular avoidable admissions (ACSC) can provide indications of the quality of ambulatory medical care10. ACSC incidence and associated hospitalisations are are widely used as indicators of the accessibility, quality, and effectiveness of ambulatory healthcare, as these reflect conditions for which timely and effective outpatient care can prevent disease progression, complications, and subsequent hospitalizations21. Lower admission rates suggest more effective primary care management of cardiovascular diseases in HZV, including prevention and treatment. The rates of hospital admissions in this cohort decreased over time and the difference between HZV and SC widened indicating the long-term sustainability of this care model. Hospital based care is often associated with higher healthcare costs in comparison to ambulatory primary care management of chronic conditions22, and the demonstrated benefits of HZV programme participation suggest that the wider implementation of this sustainable model could reduce healthcare costs for this patient group. The synergistic effects of this multifaceted intervention may have contributed to the observed outcomes. Enhanced multidisciplinary case management, quality management measures and integration of disease management programmes (DMP) in this care programme have likely played an important role.

All-cause mortality rates in this group were higher at the start of the study but sank progressively over the course of the study with incremental improved outcomes in the HZV group in comparison to SC from 2014 onwards. Statin prescription rates increased steadily in both groups over the study period but remain lower than would be expected for secondary prevention, where lipid lowering therapy is clearly indicated23,24. This indicates potential for further optimisation of secondary prevention as comprehensive care and promotion of health protective lifestyle factors must be supplemented with effective pharmacological treatment.

The findings of this study align with current discussions regarding future models of primary care and realigning the focus of healthcare from treatment to prevention in primary care25. Ageing populations and rising expenditures for chronic care highlight the importance of prevention of chronic cardiovascular diseases. Despite long-term reductions in CVD mortality, the rate of reductions have slowed, whereas morbidity continues to rise26. These changes could have significant financial implications for healthcare providers. In order to manage the increasing healthcare demands of the populations living with chronic illnesses, healthcare systems must prioritize cost-effective strategies. Strengthening primary care and service integration are key approaches that can achieve better long-term health outcomes whilst controlling costs efficiently27. GP first contact, comprehensiveness of care, continuity of care, coordinated care and person-centeredness have been identified as key components of effective primary care25 which are incorporated into the HZV programme.

One further aspect of HZV is closer collaboration with medical specialties, including cardiologists. Patients can opt into the additional on-top ambulatory specialist care programme. This allows timely access to specialist appointments, closer communication between GPs and complementary integration of quality management in parallel GP and specialist contracts. Two thirds of HZV patients were also registered for on-top ambulatory specialist care. Strengthened collaborative care is likely to have played a role in reduced hospital admissions and mortality. The additional benefits of collaborative cardiological care, within the HZV programme, have been previously described13.

Strengths and limitations

A major strength of this study lies in its comparison of intervention groups with control groups receiving standard care, rather than simply contrasting programme participants with non-enrolled patients. This design enhances the representativeness of the sample by focusing on patients who actively use healthcare services.

Nevertheless, the study has several limitations related to data analysis and potential selection bias. As is typical for studies based on secondary data, the analysis relied on the quality of data, including the accuracy of insurance claims coding. Important clinical variables, such as diagnostic and prognostic factors (e.g. blood pressure or cholesterol values) were unavailable for adjustment, which may have resulted in residual confounding. Although the GP-centred healthcare programme was introduced in 2008, the study period began in 2011 due to limitations in the completeness and reliability of earlier data. Consistent and comprehensive patient information, including accurate documentation of deceased individuals, only became available from 2010 onward. Earlier years were therefore excluded to reduce potential bias and ensure data robustness.

In addition, the observational study design and lack of randomisation prevent causal conclusions, meaning the findings should be interpreted with caution. At the start of the programme, the intervention group had a lower proportion of hospitalised patients than the control group, which may have led to an overestimation of the programme’s impact.

The voluntary nature of programme participation represents a further limitation, as both patients and GPs may have self-selected into the programme. Those who chose to participate may have been more receptive to structured care and adherence to guideline-based treatment, suggesting that some of the observed effects could be attributable to the participating GPs rather than the programme itself. Additionally, HZV participation may be associated with differences in practice characteristics, structural or organisational factors relating to care delivery. To minimize confounding, we adjusted for all available socioeconomic, clinical risk factors, and practice variables captured in the claims data. However, these data do not permit further adjustment for unmeasured confounders or behavioural factors.

To better address these limitations, randomised controlled trials are required to provide a more rigorous evaluation of the programme. Given the rising costs of healthcare delivery for the management of chronic non-communicable diseases, strengthening structured primary care initiatives could be a potential approach to reducing hospital utilisation. Reinforcing primary care with a focus on preventative care should be a key priority for healthcare systems worldwide.

Conclusion

These findings emphasise the role of structured, coordinated primary care in strengthening care for patients with CAD and indicate the long-term sustainability of this care model. The broader implementation of GP-centred care models could be considered for as a long-term strategy to strengthen primary care delivery.

Data availability

The data that support the findings of this study are available from the statutory health insurance provider AOK Baden-Württemberg but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data codes used for analyses are however available from the authors upon reasonable request and with permission of AOK Baden-Württemberg. Requests should be addressed to co-author: Dr K. Karimova, Institute of General Practice, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.

References

  1. Eurostat. Causes of death - deaths by country of residence and occurrence, (2022).

  2. Luengo-Fernandez, R. et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. Eur. Heart J. 44, 4752–4767. https://doi.org/10.1093/eurheartj/ehad583 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  3. OECD. Health at a Glance 2025: Germany. (2025).

  4. Wissenschaftliches Institut der AOK (WIdO). Gesundheitsatlas Deutschland. Available at https://www.gesundheitsatlas-deutschland.de/?selectedDisease=khk

  5. 35. Deutscher Herzbericht Update. (2024). Available at https://epaper.herzstiftung.de/#14 (2024).

  6. Destatis Per capita costs of illness for men and women continue to converge. (2025). Available at https://www.destatis.de/EN/Press/2022/07/PE22_316_236.html

  7. Jasilionis, D., van Raalte, A. A., Klüsener, S. & Grigoriev, P. The underwhelming German life expectancy. Eur. J. Epidemiol. 38, 839–850. https://doi.org/10.1007/s10654-023-00995-5 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Emmert-Fees, K. M. F., Luhar, S., O’Flaherty, M., Kypridemos, C. & Laxy, M. Forecasting the mortality burden of coronary heart disease and stroke in Germany: National trends and regional inequalities. Int. J. Cardiol. 393, 131359. https://doi.org/10.1016/j.ijcard.2023.131359 (2023).

    Article  PubMed  Google Scholar 

  9. Steppuhn, H. et al. Temporal trends in mortality due to coronary heart disease in Germany from 1998 to 2023. J. health Monit. 10, e13178. https://doi.org/10.25646/13178 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sundmacher, L. et al. Which hospitalisations are ambulatory care-sensitive, to what degree, and how could the rates be reduced? Results of a group consensus study in Germany. Health Policy. 119, 1415–1423. https://doi.org/10.1016/j.healthpol.2015.08.007 (2015).

    Article  PubMed  Google Scholar 

  11. OECD & European Observatory on Health Systems and Policies. Germany: Country Health Profile 2023 (OECD, 2023).

  12. Sterling, M. R. et al. The Role of Primary Care in Achieving Life’s Essential 8: A Scientific Statement From the American Heart Association. Circ. Cardiovasc. Qual. Outcomes. 17, e000134. https://doi.org/10.1161/HCQ.0000000000000134 (2024).

    Article  PubMed  Google Scholar 

  13. Sawicki, O. A. et al. Intensified ambulatory cardiology care: effects on mortality and hospitalisation-a comparative observational study. Sci. Rep. 10 https://doi.org/10.1038/s41598-020-71770-9 (2020).

  14. Amberger, O. A., Glushan, A., Müller, A., Beyer, M. & Karimova, K. Overview article: Impact of primary and secondary care collaboration on hospitalization for chronic heart failure: Two comparative studies. Z. Evid. Fortbild. Qual. Gesundhwes. 182–183, 125–129. https://doi.org/10.1016/j.zefq.2023.08.002 (2023).

    Article  PubMed  Google Scholar 

  15. Karimova, K., Friedmacher, C. M., Lemke, D. & Glushan, A. Development of diabetes complications within coordinated and structured primary healthcare (2011–2020): a 10 year retrospective cohort study of over 200,000 patients in Germany. BJGP open. https://doi.org/10.3399/BJGPO.2024.0061 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  16. Friedmacher, C. et al. Enhanced crisis resilience of general practitioner-centred care: a retrospective cohort study of patients with coronary artery disease during the COVID-19 pandemic in Germany. BMC Prim. Care. 26, 225. https://doi.org/10.1186/s12875-025-02917-8 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kateryna Karimova et al. Evaluation der Hausarztzentrierten Versorgung (HZV) nach § 73b SGB V und der Facharztverträge nach § 140a SGB V in Baden- Württemberg Studienphase 2021 bis 2022. (2023). Available at https://www.neueversorgung.de/images/2023/08_23/Ergebnisbericht_21-22_Universitt_Frankfurt_am_Main_Teil_2A.pdf

  18. Freund, T. Determinants and consequences of potentially avoidable hospitalizations for ambulatory care sensitive conditions. BMBF 2012_ACSC Studienprotokoll.

  19. Karimova, K. et al. Reduction of adverse clinical outcomes among older patients within a structured primary care programme: findings from a 12-year cohort study in Germany (2010-22). Age Ageing. 54 https://doi.org/10.1093/ageing/afaf310 (2025).

  20. Kuhbandner, C. & Reitzner, M. Regional patterns of excess mortality in Germany during the COVID-19 pandemic: a state-level analysis. Royal Soc. open. Sci. 12, 250790. https://doi.org/10.1098/rsos.250790 (2025).

    Article  Google Scholar 

  21. WHO Regional Office for Europe. Assessing health services delivery performance with hospitalizations for ambulatory care sensitive conditions. (2016).

  22. Atun, R. What are the advantages and disadvantages of restructuring a health care system to be more focused on primary care services? World Health Organization. Regional Office for Europe. (2004). Available at https://iris.who.int/items/91aec323-2dac-46a6-8f07-4a641e4371a6

  23. National Institute for Health and Clinical Excellence (Great Britain). Cardiovascular disease: risk assessment and reduction, including lipid modification NICE guideline Reference number:NG238. (2023). Available at https://www.nice.org.uk/guidance/ng238

  24. Vrints, C. et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur. Heart J. 45, 3415–3537. https://doi.org/10.1093/eurheartj/ehae177 (2024).

    Article  CAS  PubMed  Google Scholar 

  25. Allen, L. N. et al. Models of global primary care post-2030. Lancet Prim. care. 1, None. https://doi.org/10.1016/j.lanprc.2025.100027 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  26. Stewart, J., Addy, K., Campbell, S. & Wilkinson, P. Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature. JRSM Cardiovasc. disease. 9, 2048004020949326. https://doi.org/10.1177/2048004020949326 (2020).

    Article  Google Scholar 

  27. Polanco, B., Oña, A. & Gemperli, A. Pacheco Barzallo, D. Excess healthcare utilization and costs linked to chronic conditions: a comparative study of nine European countries. Eur. J. Pub. Health. 35, 216–227. https://doi.org/10.1093/eurpub/ckaf012 (2025).

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge AOK Baden-Württemberg for providing the claims data and the aQua-Institute, Göttingen, Niedersachsen, Germany for preparing the data.

Funding

Open Access funding enabled and organized by Projekt DEAL. The independent evaluation of GP-centred healthcare in the German regional state of Baden-Württemberg was funded by AOK Baden- Württemberg, Association of General Practitioners Baden-Württemberg (Hausärzteverband und HÄVG), and MEDI Baden-Württemberg.

Author information

Authors and Affiliations

  1. Goethe University Frankfurt, Institute for General Practice, Frankfurt am Main, Hessen, Germany

    Catriona Friedmacher, Anastasiya Glushan, Justyna Wuenstel & Kateryna Karimova

  2. Insitute for Medical Informatics, Biometry und Epidemiology (AMIB), Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany

    Renate Klaaßen-Mielke

Authors

  1. Catriona Friedmacher
  2. Anastasiya Glushan
  3. Justyna Wuenstel
  4. Renate Klaaßen-Mielke
  5. Kateryna Karimova

Contributions

CF - formal analysis and interpretation of data, drafting and revising of the manuscript JW - formal analysis and interpretation of data, drafting and revising of the manuscript AG - formal analysis and interpretation of data, drafting and revising of the manuscript RKM - formal analysis and interpretation of data, drafting and revising of the manuscript KK - conceptualization and design, formal analysis and interpretation of data, drafting and revising of the manuscript.

Corresponding author

Correspondence to Catriona Friedmacher.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

This study was submitted to the Ethics Committee of the Faculty of Medicine at the Goethe University, Frankfurt am Main under the reference number 470/13. The waiver is based on the principles outlined in the Declaration of Helsinki and the German Professional Code for Physicians (§ 15). According to the ethics committee, an approval is not required for studies that exclusively rely on fully anonymized secondary data from health insurance records. As this study does not involve direct patient contact or identifiable personal data, the Ethics Committee of the Faculty of Medicine at the Goethe University, Frankfurt am Main determined that a formal ethics vote is unnecessary and that informed consent is not applicable in this case. All methods are performed in accordance with the relevant guidelines and regulations.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Friedmacher, C., Glushan, A., Wuenstel, J. et al. Sustained long-term benefits of structured primary care for patients with coronary artery disease: a 12-year cohort study in Germany (2011–2022). Sci Rep 16, 36729 (2026). https://doi.org/10.1038/s41598-026-78603-1

Download citation

  • Received: 17 March 2026

  • Accepted: 27 October 2026

  • Published: 03 November 2026

  • Version of record: 03 November 2026

  • DOI: https://doi.org/10.1038/s41598-026-78603-1

Keywords

来源:Nature 健康护理主题 · nature.com